Disclosure of inside information according to Article 17 MAR.
12 November 2019 | 14:07 hrs CET/CEST
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, INTO OR WITHIN THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO DISTRIBUTE THIS ANNOUNCEMENT.
Disclosure of inside information according to Article 17 MAR.
4SC AG secures circa EUR 22.4 million from a capital increase
Planegg-Martinsried, Germany, 12 November 2019 – 4SC AG (4SC, FSE Prime Standard: VSC) hereby announces the completion of its capital increase resolved in principle on 7 October 2019. A total of 10,647,553 offered shares were placed at a subscription price of EUR 2.10 resulting in gross proceeds of circa EUR 22.4 million. The existing shareholders of the Company, Santo Holding (Deutschland) GmbH and ATS Beteiligungsverwaltung GmbH, have each exercised their respective subscription rights in full and have been allocated a substantial part of the remaining new shares.
The Management Board of 4SC AG today resolved, with the approval of the Supervisory Board, to increase 4SC’s share capital from EUR 35,325,216.00, composed of 35,325,216 no-par value bearer shares, by EUR 10,647,553.00 or 10,647,553 shares to a total of EUR 45,972,769.00, composed of 45,972,769 shares. Trading of the new shares on the Frankfurt Stock Exchange is anticipated to commence on 19 November 2019 after registration of the implementation of the capital increase with the Commercial Register, which is expected to occur on 14 November 2019.
—————————————————————————
Information and Explanation of the Issuer to this News:
About 4SC
4SC AG is a clinical-stage biopharmaceutical company developing small-molecule drugs that can target key indications in cancer with high unmet medical needs. 4SC’s pipeline is protected by a comprehensive portfolio of patents and currently comprises two drug candidates in clinical development: resminostat and domatinostat.
4SC aims to generate future growth and enhance its enterprise value by entering into partnerships with pharmaceutical and biotech companies and/or the eventual marketing and sales of approved drugs in select territories by 4SC itself.
4SC is headquartered in Planegg-Martinsried near Munich, Germany. The Company had 47 employees as of 30 September 2019 and is listed on the Prime Standard of the Frankfurt Stock Exchange (FSE Prime Standard: VSC; ISIN: DE000A14KL72).
Forward-looking information
Information set forth in this ad-hoc release contains forward-looking statements, which involve risks and uncertainties. The forward-looking statements contained herein represent the judgement of 4SC as of the date of this ad-hoc release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond 4SC’s control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. 4SC expressly disclaims any obligation or undertaking to release any updates or revisions to any such statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.
Disclaimer
The public offer of the offered shares in the Company has closed. There is no possibility to subscribe for securities of the Company anymore.
This notification is not intended to constitute, and should not be construed as, an offer to sell or subscribe for, or the announcement of a forthcoming offer to sell or subscribe for, or a solicitation of any offer to buy or subscribe for, or the announcement of a forthcoming solicitation of any offer to buy or subscribe for, ordinary shares in the share capital of 4SC AG (the “Company“, and such shares, the “Shares“).
In particular, this notification is not an offer of securities for sale in the United States. Securities may not be offered or sold in the United States absent registration under the U.S. Securities Act of 1933, as amended (the “Securities Act”) or an exemption from registration. The Shares have not been and will not be registered under the Securities Act. No public offering of the Shares was conducted in the United States.
Neither this notification nor any copy of it may be taken or transmitted, directly or indirectly, into the United States, Australia, Canada, Japan or the South Africa.
Contact
Jason Loveridge, PhD
CEO
email hidden; JavaScript is required
+49 89 700763-0